Yangzhou Prince Chemical Co., Ltd. was established in 2003, specializing in the research, development, and production of novel pharmaceutical intermediates. The company covers an area of 20,000 square meters, with fixed assets of 25 million yuan, annual sales reaching 70 million yuan, and annual taxes of nearly 3 million yuan.

In recent years, the company has developed over 20 key intermediates in areas such as anticancer, cardiovascular, and mental health, including Quetiapine intermediates, Fluvoxamine intermediates, Erlotinib intermediates, Gefitinib intermediates, Rabeprazole intermediates, and Aliskiren intermediates. It supplies high-quality pharmaceutical intermediates to several globally renowned pharmaceutical companies. Ten of its products have been recognized as "High-Tech Products of Jiangsu Province," and in 2011, the company was awarded the title of "High-Tech Enterprise."

The company adheres to a path of technological innovation, maintaining long-term and positive collaborations with Zhejiang University and China Pharmaceutical University. In partnership with Jiangsu Vcare Pharmaceutical Technology Co., Ltd., it has established a large pharmaceutical R&D platform in Nanjing Pukou High-Tech Zone. The company also operates a Jiangsu Provincial Engineering Technology Center, with annual R&D investment exceeding 2 million yuan and over 10 new products successfully developed each year. In recent years, it has applied for more than 10 invention patents, with 3 already granted. In 2007 and 2008, the company undertook two National Torch Program projects.

The company insists on using international standard management systems to advance all aspects of its operations, having established ISO9001:2000 Quality Management System, ISO14001:2004 Environmental Management System, and OHS18001:1999 Occupational Health and Safety Management System.